# Novo Nordisk CEO Ousted Amid Ozempic Troubles  ## Metadata - Author: [[Sam Klebanov]] - Full Title: Novo Nordisk CEO Ousted Amid Ozempic Troubles - Category: #articles - Summary: Novo Nordisk's CEO, Lars Fruergaard Jorgensen, is stepping down due to recent market challenges and a significant drop in the company’s stock price. The company is facing stiff competition from Eli Lilly's drugs, which have outperformed Novo's products in sales growth. Additionally, Novo has downgraded its sales projections as sales of its popular drugs, Ozempic and Wegovy, have declined. - URL: https://www.morningbrew.com/stories/2025/05/17/novo-nordisk-ceo-ousted-amid-ozempic-troubles?utm_source=&utm_medium=syndication&utm_campaign=feed ## Highlights - longtime CEO Lars Fruergaard Jorgensen is [stepping down](https://www.healthcare-brew.com/stories/2025/05/16/novo-nordisk-ousts-ceo). ([View Highlight](https://read.readwise.io/read/01jvfbs2ms8d3c36pa5tdaj4f1)) - Lost MVP title No longer the most valuable company in Europe, Novo has been losing momentum as the competition breathes down its neck: • Eli Lilly’s weight loss and diabetes drugs, Zepbound and Mounjaro outpaced Ozempic and Wegovy in sales growth last year. And clinical trials showed Zepbound to be more effective than Novo’s weight loss product. • In addition, Lilly is developing a daily obesity pill, while trials for Novo’s next-gen weight loss treatment, CagriSema, [delivered underwhelming results](https://www.wsj.com/health/pharma/novo-nordisks-shares-tank-after-experimental-obesity-jab-misses-target-338aeeeb?mod=article_inline). ([View Highlight](https://read.readwise.io/read/01jvfbqgh8719w6r95n8yj0n0e)) - The company recently downgraded its sales growth projections for the year, as it reported Q1 Wegovy and Ozempic sales declined by 13% and 3%, respectively, from the previous quarter. ([View Highlight](https://read.readwise.io/read/01jvfbrdjs8kwna98hk6czm8t4))